Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 10, 2016 11:27 AM ET

Health Care Technology

Company Overview of Millennium Health, LLC

Company Overview

Millennium Health, LLC develops and operates cloud based clinically actionable information solutions for the treatment decisions for patients. The company provides solutions for medication monitoring, pharmacogenetic testing, urine drug testing (UDT), and oral fluid testing (OFT) services. Its solutions include RxAnte System, an analytics platform that includes predictive and decision analytics, advanced evaluation methods, and a cloud-based platform that equips health care professionals, such as payers, pharmacy benefit management companies, and providers to improve medication outcomes for patients at the population or individual level; Millennium UDT Rapid Assessment Drug Adherence report ...

16981 Via Tazon

Suite F

San Diego, CA 92127

United States

Founded in 2007

Phone:

858-451-3535

Fax:

858-451-3636

Key Executives for Millennium Health, LLC

Chief Executive Officer and Director
Age: 48
President
Age: 53
Chief Financial Officer
President of Rxante
Chief Scientific Officer and Senior Vice President
Compensation as of Fiscal Year 2015.

Millennium Health, LLC Key Developments

Millennium Health Announces Board Appointments

Millennium Health announced the appointment of Ronald A. Rittenmeyer as the new chairman of the board of directors, and the addition of two new outside directors, Eugene I. Davis and Stephen Gray, effective immediately. Brock Hardaway, currently chief executive officer of Millennium Health, will also join the board as its fourth and only officer member. Ron Rittenmeyer is the retired chairman, president and chief executive officer of Electronic Data Systems (EDS). Rittenmeyer also served as chairman, president and chief executive officer of Expert Global Solutions, which he led through reorganization. Previously, he served as chairman, president and chief executive officer of Safety-Kleen Inc., which he successfully led through Chapter 11 bankruptcy protection and into a successful reorganization. Among his other leadership roles, Rittenmeyer was CEO and president of AmeriServe; chairman, CEO and president of RailTex Inc.; president and COO of Ryder TRS Inc.; president and COO of Merisel; and COO of Burlington Northern Railroad. Rittenmeyer was also with PepsiCo's Frito Lay and PepsiCo's Foods International Divisions for 20 years in senior management roles. Rittenmeyer is currently on the board of directors of American International Group Inc. (AIG), Tenet Healthcare Corporation, IMS Health Inc. and a director for Avaya Inc. Gene Davis is chairman and chief executive officer of PIRINATE Consulting Group, LLC. Stephen Gray is a managing member of Gray & Company, with over forty years of experience leading the successful restructuring of companies. He previously led the Fiduciary Services Practice at Deloitte, and was a senior managing partner at CRG Partners, which Deloitte acquired in 2012.

Millennium Health to Provide Urine Drug Testing for a U.S. Food and Drug Administration Approved Clinical Trial

Millennium Health announced it has been selected to provide urine drug testing (UDT) for a U.S. Food and Drug Administration (FDA) approved clinical trial. Data from the trial will be used to help estimate the serious risk for the development of hyperalgesia following use of extended-release long-acting (ER/LA) opioid analgesics to treat chronic pain for at least one year. The trial will also assess the development of tolerance following use of ER/LA opioid analgesics and include an assessment of risk relative to efficacy. In September 2013, the FDA announced a series of post-marketing requirements for manufacturers of ER/LA opioid analgesic products. Nine manufacturers of these medications formed a consortium known as the Opioid Post-marketing Requirement Consortium (OPC) to carry out research aimed at understanding safe and appropriate use for chronic pain. After a rigorous review process, Millennium was selected by OPC to provide UDT services, expert consultation, and research collaboration on the clinical trial. Millennium's contract award could be valued at up to $1.6 million dollars at the completion of the clinical trial. The multicenter study is randomized, double-blind, placebo-controlled clinical trial of structured opioid discontinuation versus continued opioid therapy in suboptimal and optimal responders to high-dose, long-term opioid analgesic therapy for chronic pain. Approximately 3,280 subjects will be screened and several hundred will go on to participate.

Millennium Health to Pay $256 Million to Resolve False Claims Charge

Millennium Health has agreed to pay $256 million to resolve alleged violations of the False Claims Act for billing Medicare, Medicaid and other federal health care programs for medically unnecessary urine drug and genetic testing and for providing free items to physicians who agreed to refer expensive laboratory testing business to Millennium. Millennium has agreed to pay $227 million to resolve False Claims Act allegations, detailed in a complaint filed by the United States, that Millennium systematically billed federal health care programs for excessive and unnecessary urine drug testing from Jan. 1, 2008, through May 20, 2015. The United States alleged that Millennium caused physicians to order excessive numbers of urine drug tests, in part through the promotion of "custom profiles," which, instead of being tailored to individual patients, were in effect standing orders that caused physicians to order large number of tests without an individualized assessment of each patient's needs. Millennium has also agreed to pay $10 million to resolve False Claims Act allegations that it submitted false claims to federal health care programs from Jan. 1, 2012, through May 20, 2015, for genetic testing that was performed routinely and without an individualized assessment of need. In connection with the False Claims Act settlements, Millennium has also entered into a corporate integrity agreement (CIA) with the Department of Health and Human Services-Office of Inspector General (HHS-OIG). In addition, Millennium will pay $19.2 million to the Centers for Medicare and Medicaid Services (CMS) to resolve certain administrative actions related to Millennium's urine drug test billing practices.

Similar Private Companies By Industry

Company Name Region
Parkridge Hospital, Inc United States
Franklin Memorial Hospital Inc United States
Reconceived, LLC United States
Mass Behavioral Health Partnership United States
Randolph County Medical Center United States

Recent Private Companies Transactions

Type
Date
Target
Bankruptcy
November 10, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Millennium Health, LLC, please visit www.millenniumhealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.